Eberconazole, an Antifungal

1049 Words3 Pages

Summary
I chose to summarize an article about a new antifungal called eberconazole. Twenty to twenty-five percent of the world’s population is affected by a dermatophytic infection. This is a parasitic skin infection caused by a fungus. The most common species of fungi to cause dermatophytosis are Trichophyton, Epidermophyton, and Microsporum. It is caused by parasitic organisms attaching to the keratin on the skin. They feed on the keratin and form colonies. These infections are only limited to the superficial layers of the skin so topical antifungal agents are a great treatment. Although oral and topical antifungals can be used, topical treatments are the first line drugs of choice for localized dermatophytosis due to a decrease in the amount of adverse reactions, increased efficacy and aim in treatment, shorter treatment period needed, ease of use and application, decrease in treatment time, and increased compliance. There are a lot of antifungals on the market and choosing the best drug for treatment is made harder due to problems with diagnosing the infection, signs and symptoms that are not the norm for clinical presentation, the prevalence of drug resistant strains, the increasing population of immunocompromised people, and poor adherence to treatment. Eberconazole is an imidazole derivative that was originally launched on the market in Spain in 2005 by Laboratories Salvat and is now on the market in many countries. This article reviews the pharmacology of this drug and its clinical use and efficacy.
The molecular structure of eberconazole is C18H14Cl2N2. It is a broad spectrum antifungal that has be proven to be successful in fighting dermatophytosis, candidiasis, other yeast infections including Malassezzia furfur...

... middle of paper ...

...eberconazole besides this article and it seems like a promising drug for the future. It makes me want to keep watching for its emergence in the United States. It is currently being used in many other countries besides the U.S. It is possible to come across patients who may be using this drug because they obtained it elsewhere. The more knowledge we have about drugs that are being studied or are available in other countries can better help us treat patients that may be using these drugs. I will continue to watch for this drug to become available in the U.S. so that I may be able to use it in my practice someday.

Works Cited

Moodahadu-Bangera, L. S., Martis, J., Mittal, R., Krishnankutty, B., Kumar, N., Bellary, S., ... Rao, P. K. (2012). Eberconazole-Pharmocological and clinical review. Indian Journal of Dermatology, Venereology, and Leprology, 78(2), 217-222.

Open Document